Multiple Myeloma

EU Regulator Starts its Review of Cidara Therapeutics’ Candidiasis Therapy Rezafungin The EU regulator has begun its review of Cidara Therapeutics’ once-weekly antifungal rezafungin, with a decision expected next year as a new option for serious, invasive candida infections. The application is based on the ReSTO...

Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...

FDA Grants Orphan Drug Designation to Evorpacept for AML ALX Oncology Holdings announced that the U.S. Food and Drug Administration had granted orphan drug designation to Evorpacept, a next-generation CD47 blocker, for treating patients with acute myeloid leukemia (AML). Acute Myeloid Leukemia (AML) is an agg...

Bristol-Myers Squibb’s Opdivo Gets FDA Approval for Esophageal Cancer The FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced Esophageal Cancer, encroaching on the territory belonging to Merck & Co’s rival Keytruda. The latest...

GSK Acquires Sierra Oncology for USD 1.9 Billion GlaxoSmithKline has agreed to buy Sierra Oncology and its lead drug assets, momelotinib, for anemia caused by the blood malignancy myelofibrosis. GSK is paying USD 55 per share in cash for Sierra, a 39% premium to the company's closing share price yesterday, valui...

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...

Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on ha...

Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company’s lead program developing treatments for C...

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon Pfizer and Opko had joined hands in 2014 to develop somatrogon, a pediatric growth hormone deficiency (GHD) drug. It comprises the natural sequence of growth hormone and a copy of the C-terminal peptid...